BARCELONA, Spain | Sep 07, 2006 | The Business Intelligence firm La Merie S.L. reported today that the advent of anti-TNF biologicals has set a new standard of treatment in moderate to severe plaque-type psoriasis. Systemic anti-TNF biologics etanercept followed by infliximab, adalimumab and certolizumab pegol have raised the level of efficacy in an unprecedented manner, but which next generation biologics such as Centocor’s CNTO 1275 directed against interleukin-12/-23 also achieved in phase II. The more than 13 biologics and 31 small molecule projects in the full clinical stage pipeline will have to be smarter than anti-TNF and achieve at least the same efficacy but offer an advantage in avoiding the serious side effects of anti-TNF biologics. These results and more were found in a competitor analysis conducted by La Merie Business Intelligence. The findings of the search can be acquired at www.pipelinereview.com, La Merie’s News Center and Online Store.
